III - Information Services Group, Inc. 0 WATCHERS

Why didn't they add MSTR then I'd honestly feel better with Saylor Moon in the index than Fraud III and Fraud II

Neat. Meanwhile, the Artemis III crewed moon landing keeps getting pushed back, to the point where we'll be neck-and-neck with China's moon mission in 2030. They keep meeting all their launch deadlines while the US is busy with our insipid corporate drama. At this rate, they're going to beat us …

GT-02287 addresses multiple potential sources of Parkinson's ($GANX) What’s the first domino in Parkinson’s disease? **Mainstream science points to the lysosome and α-synuclein aggregation—the idea that misfolded α-syn builds up because the lysosomal “trash system” breaks down. But what if that’s not where the problem starts?** The recent Neuroscience poster …

Act III of the AI bubble story arc is underway. Act IV will not be as pleasant.

3i Group: III.L The leading FTSE 100 private equity company 3I group (III.L) is currently trading at close to its NAV value, closing at 2,999p today. It is down around 30% off its peak due to softening demand of like-for-like sales in France, impacting their largest holding: Action, a big …

Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech. **The set-up that Gain Therapeutics has right now is extremely rare, IMO. Largely de-risked, and is only a week or two away from releasing what is likely some of the most compelling evidence of …

$SHFS Market Cap: \~$4.5M Low float high alpha rocket with a chart that screams multi bagger. Technicals: RSI <30 (deeply oversold), bouncing off 52-week lows, low float = explosive potential. Business: Huge moat and specialty play. The #1 compliant banking/fintech for cannabis. Provides checking, loans, cash management, and compliance tools …